• Fusen Pharmaceutical received China NMPA clearance to market doxazosin mesylate extended-release tablets for hypertension, benign prostatic hyperplasia symptoms.
• The drug is a selective alpha-1 blocker; it is the group’s first sustained-release product using laser-drilling technology.
• Menet data cited in the filing put 2025 China sales for the drug class above RMB 800 million, up 27.88% year on year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fusen Pharmaceutical Company Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260710-12241619), on July 10, 2026, and is solely responsible for the information contained therein.